.jetcityimage/iStock Content via Getty Images Morgan Stanley has selected Eli Lilly (NYSE: LLY) as its best biopharma selection for 2025 as well as rated one more 9 labels in the room as over weight. The investment bank claimed in a details that it continues to think “diabesity is readied to end up being.